The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Treatment of Smoldering Myeloma Cuts Progression Rate in Half

2.

Clinical trial sees dramatic results using radiation to treat breast cancer

3.

Kate Middleton Announces Major Cancer Update

4.

Checking PSA levels too soon after prostate cancer surgery can lead to overtreatment, study suggests

5.

ASTRO Guideline Addresses Specifics of HPV-Associated Oropharyngeal Cancer


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot